Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

(2017) Frederick Arce Vargas et al.   IMMUNITY

Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer

(2017) Nicholas A. Taylor et al.   JOURNAL OF CLINICAL INVESTIGATION

New development in CAR-T cell therapy

(2017) Zhenguang Wang et al.   Journal of Hematology & Oncology

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

De-novo and acquired resistance to immune checkpoint targeting

(2017) Nicholas L Syn et al.   LANCET ONCOLOGY

Epigenetics and immunotherapy: The current state of play

(2017) Jennifer Dunn et al.   MOLECULAR IMMUNOLOGY

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

(2017) Riccardo Mezzadra et al.   NATURE

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

(2017) Jingjing Zhu et al.   Nature Communications

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

(2017) Jon Bjoern et al.   Oncotarget

Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes

(2017) Xinqi Wu et al.   Cancer Immunology Research

Myeloid-Derived Suppressor Cells

(2017) Dmitry I. Gabrilovich   Cancer Immunology Research

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

(2017) Zibing Wang et al.   OncoImmunology

Tumor-infiltrating CD39+ γδTregs are novel immunosuppressive T cells in human colorectal cancer

(2017) Guoming Hu et al.   OncoImmunology

Microbiome and Anticancer Immunosurveillance

(2016) Laurence Zitvogel et al.   CELL

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

(2016) Donnele Daley et al.   CELL

Regulatory T cells in cancer immunotherapy

(2016) Atsushi Tanaka et al.   CELL RESEARCH

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

Interleukin-35 Limits Anti-Tumor Immunity

(2016) Meghan E. Turnis et al.   IMMUNITY

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion

(2016) Bertram Bengsch et al.   IMMUNITY

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

(2016) Frank A. Schildberg et al.   IMMUNITY

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

(2016) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance

(2016) Kuo-Hsing Chen et al.   Journal of Hematology & Oncology

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

(2016) Weijie Ma et al.   Journal of Hematology & Oncology

Emerging therapeutic agents for lung cancer

(2016) Bhagirathbhai Dholaria et al.   Journal of Hematology & Oncology

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

(2016) Takuro Saito et al.   NATURE MEDICINE

Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets

(2016) Yufang Shi et al.   NATURE REVIEWS DRUG DISCOVERY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?

(2016) Amer A Beg et al.   Epigenomics

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

(2016) Eloah Rabello Suarez et al.   Oncotarget

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis

(2015) Juan R. Cubillos-Ruiz et al.   CELL

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses

(2015) Ping-Chih Ho et al.   CELL

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

(2015) C. Gebhardt et al.   CLINICAL CANCER RESEARCH

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

T cell metabolism drives immunity

(2015) Michael D. Buck et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immunometabolism governs dendritic cell and macrophage function

(2015) Luke A.J. O’Neill et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CTLA-4 Blockade Plus Adoptive T-Cell Transfer Promotes Optimal Melanoma Immunity in Mice

(2015) David A. Mahvi et al.   JOURNAL OF IMMUNOTHERAPY

Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression

(2015) Kevin J Curran et al.   MOLECULAR THERAPY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Big opportunities for small molecules in immuno-oncology

(2015) Jerry L. Adams et al.   NATURE REVIEWS DRUG DISCOVERY

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

(2015) Kathrin Schumann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Combined Immune Checkpoint Blockade

(2015) Charles G. Drake   SEMINARS IN ONCOLOGY

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model

(2015) L. Wang et al.   Cancer Immunology Research

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

(2015) D. S. Thommen et al.   Cancer Immunology Research

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

(2015) T. Higuchi et al.   Cancer Immunology Research

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Role of Local Radiation Therapy in Cancer Immunotherapy

(2015) Sandra Demaria et al.   JAMA Oncology

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function

(2014) Andrew N. Macintyre et al.   Cell Metabolism

Molecular Pathways: Myeloid Complicity in Cancer

(2014) I. M. Stromnes et al.   CLINICAL CANCER RESEARCH

Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

(2014) T. C. van der Sluis et al.   CLINICAL CANCER RESEARCH

γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer

(2014) Pin Wu et al.   IMMUNITY

The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection

(2014) Matthew M. Staron et al.   IMMUNITY

Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection

(2014) Pablo Penaloza-MacMaster et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

(2014) Rituparna Das et al.   JOURNAL OF IMMUNOLOGY

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date

(2014) Daniel P. Mould et al.   MEDICINAL RESEARCH REVIEWS

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

γδ T cell surveillance via CD1 molecules

(2014) Adrienne M. Luoma et al.   TRENDS IN IMMUNOLOGY

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

(2014) J. Yuan et al.   Cancer Immunology Research

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

(2014) Z. A. Cooper et al.   Cancer Immunology Research

Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses

(2014) Rebecca R. Laborde et al.   Frontiers in Immunology

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer

(2013) Xiaoqiang Tang   CANCER LETTERS

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

(2013) Chih-Hao Chang et al.   CELL

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Combining cancer immunotherapy and targeted therapy

(2013) Antoni Ribas et al.   CURRENT OPINION IN IMMUNOLOGY

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

Control of inflammation by integration of environmental cues by regulatory T cells

(2013) Ashutosh Chaudhry et al.   JOURNAL OF CLINICAL INVESTIGATION

KIT oncogene inhibition drives intratumoral macrophage M2 polarization

(2013) Michael J. Cavnar et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model

(2013) A. Sevko et al.   JOURNAL OF IMMUNOLOGY

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

Fueling Immunity: Insights into Metabolism and Lymphocyte Function

(2013) E. L. Pearce et al.   SCIENCE

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

(2013) S. Viaud et al.   SCIENCE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy

(2013) D. B. Johnson et al.   Cancer Immunology Research

Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

(2013) M. K. Callahan et al.   Cancer Immunology Research

An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer

(2013) E. B. Golden et al.   Cancer Immunology Research

Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity

(2013) Dieter Kabelitz et al.   OncoImmunology

Emerging Co-signaling Networks in T Cell Immune Regulation

(2013) Keunok Jung et al.   Immune Network

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective

(2012) D. T. Le et al.   CANCER RESEARCH

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

Densely Granulated Murine NK Cells Eradicate Large Solid Tumors

(2012) R. B. Liu et al.   CANCER RESEARCH

T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis

(2012) A. Facciabene et al.   CANCER RESEARCH

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma

(2012) K. N. Kodumudi et al.   JOURNAL OF IMMUNOLOGY

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

(2012) Joannes FM Jacobs et al.   LANCET ONCOLOGY

Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor

(2012) Megan E. Prosser et al.   MOLECULAR IMMUNOLOGY

The functions and regulation of the PTEN tumour suppressor

(2012) Min Sup Song et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

BRAF inhibition improves tumor recognition by the immune system

(2012) Marco Donia et al.   OncoImmunology

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

(2011) S. Solito et al.   BLOOD

β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas

(2011) William E. Damsky et al.   CANCER CELL

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

(2011) Dalil Hannani et al.   CANCER JOURNAL

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

(2010) S. P. Kerkar et al.   CANCER RESEARCH

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

(2010) Ingrid M.E. Desar et al.   INTERNATIONAL JOURNAL OF CANCER

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

(2010) Evan M. Hersh et al.   INVESTIGATIONAL NEW DRUGS

Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice

(2010) Ingunn M. Stromnes et al.   JOURNAL OF CLINICAL INVESTIGATION

Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling

(2010) R. S. Bhatt et al.   MOLECULAR CANCER THERAPEUTICS

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Cell-Intrinsic Transforming Growth Factor-β Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence In Vivo

(2009) Roberto Tinoco et al.   IMMUNITY

Regulatory T cells and immune tolerance to tumors

(2009) Xuefang Cao   IMMUNOLOGIC RESEARCH

Human peripheral γδ T cells possess regulatory potential

(2009) Anja A. Kühl et al.   IMMUNOLOGY

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

(2009) G. Solinas et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

(2008) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection

(2008) D. G. Brooks et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE